Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 10Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Renal Cell 4Kidney Neoplasms 2Colorectal Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Interferon-alpha × Clear all
NCT00005615 2012-09-25

Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
24 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡